Lymphatic EC response to VEGFC: Difference between revisions
From FANTOM5_SSTAR
No edit summary |
m (Autoedit moved page Lymphatic Endothelial cells response to VEGFC to Lymphatic EC response to VEGFC without leaving a redirect: NSchange) |
Revision as of 21:44, 3 February 2015
Series: | IN_VITRO DIFFERENTIATION SERIES |
---|---|
Species: | Human (Homo sapiens) |
Genomic View: | Zenbu |
Expression table: | FILE |
Link to TET: | [{{{tet_file}}} TET] |
Sample providers : | Michael Detmar |
Germ layer: | mesoderm |
Primary cells or cell line: | primary cells |
Time span: | 8 hours |
Number of time points: | 16 |
CollapseOverview |
---|
The lymphatic vasculature plays a critical role in the maintenance of tissue fluid balance, the uptake of dietary fats and the immune response. Lymphatic vessels are also actively involved in pathological conditions, in particular in promoting cancer metastasis to lymph nodes and in controlling chronic inflammatory diseases (1, 2, 3, 4). The growth of new lymphatic vessels from pre-existing vasculature is called lymphangiogenesis. The main pathway regulating lymphangiogenesis is VEGF-C signaling via its receptor VEGFR-3 on lymphatic endothelial cells. Fully mature VEGF-C has affinity for VEGFR-2 which is also expressed on lymphatic endothelial cells (LEC) (5). A mutated version of VEGF-C, VEGF-C156S, in which cysteine 156 is replaced by a serine, specifically activates VEGFR-3 but not VEGFR-2 (6). Specific activation of VEGFR-3 by VEGF-C156S is sufficient to induce lymphangiogenesis, as demonstrated in K14-VEGF-C156S mice. Upon stimulation, the receptor dimerizes and is phosphorylated at several tyrosine residues. These phosphorylation sites activate several adaptor molecules along with further downstream mediators including JNK, ERK1/2, PI3K and PKB/AKT, ultimately leading phenotypic changes of LECs. However, the exact transcriptional mediators are not fully investigated yet. These transcription factors might be essential in mediating the effect of VEGF-C and could serve as potential therapeutic targets of the lymphatic endothelium. |
ExpandSample description |
---|
ExpandQuality control |
---|
Profiled time course samples
Only samples that passed quality controls (Arner et al. 2015) are shown here. The entire set of samples are downloadable from FANTOM5 human / mouse samples